News
NICE finally backs Enhertu for HER2-low breast cancer
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
Market Access
Sponsored
Due diligence: Identifying start-up risks & gaps
hVIVO's Consulting team discusses due diligence, a structured assessment process to evaluate an asset's risk, opportunities, and value drivers.
News
Wales takes UK lead on needle-free anaphylaxis prevention
Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.
News
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
News
FDA to decide on Takeda's psoriasis blockbuster hope in Q1
The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
